Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe-/- mice

Diabetologia

Volumn 55, Issue 8, 2012, Pages 2267-2275

  Vittone, F ^a   Liberman, A ^b   Vasic, D ^a   Ostertag, R ^a   Esser, M ^b   Walcher, D ^a   Ludwig, A ^c   Marx, N ^b   Burgmaier, M ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Glucagon like peptide 1; Incretins; Plaque stability; Type 2 diabetes

Indexed keywords

COLLAGEN; GELATINASE B; GLUCAGON LIKE PEPTIDE 1; PLACEBO; RANTES; SITAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ROOT; ARTERIOSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID DIET; MACROPHAGE MIGRATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ZYMOGRAPHY;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BODY WEIGHT; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PYRAZINES; TRIAZOLES;

EID: 84866356839     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2582-5     Document Type: Article

References (38)

1. Pratley RE, Salsali A (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 23:919-931
2. Nystrom T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:E1209-E1215
3. Kim Chung le T, Hosaka T, Yoshida M et al (2009) Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 390:613-618
4. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP (2009) Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 30:1735-1741
5. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146-151
6. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q (2010) Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325:26-35
7. Kim SJ, Nian C, McIntosh CH (2010) Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T cell migration through incretin-dependent and - independent pathways. Diabetes 59:1739-1750
8. Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 58:641-651
9. Shah Z, Kampfrath T, Deiuliis JA et al (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124:2338-2349
10. Fadini GP, Avogaro A (2011) Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 55:10-16
11. Scott R, Wu M, Sanchez M, Stein P (2007) Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61:171-180
12. Mistry GC, Maes AL, Lasseter KC et al (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 48:592-598
13. Matsubara J, Sugiyama S, Sugamura K et al (2012) A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59:265-276
14. Shamshiev AT, Ampenberger F, Ernst B, Rohrer L, Marsland BJ, Kopf M (2007) Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J Exp Med 204:441-452
15. Chiba T, Kondo Y, Shinozaki S et al (2006) A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb 13:308-313
16. Mu J, Woods J, Zhou YP et al (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704
17. Underwood R, Chiravuri M, Lee H et al (1999) Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem 274:34053-34058
18. Durinx C, Lambeir AM, Bosmans E et al (2000) Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of XPro dipeptides. Eur J Biochem 267:5608-5613
19. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I (2003) Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 52:81-86
20. Marx N, Walcher D, Raichle C et al (2004) C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 24:540-545
21. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J (1998) Macrophages in human atheroma contain PPARgamma: differentiationdependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153:17-23
22. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439
23. Geelhoed-Duijvestijn PH (2007) Incretins: a new treatment option for type 2 diabetes? Neth J Med 65:60-64
24. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K (2009) Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 18:1495-1503
25. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J (2006) Glucagonlike peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res 55:352-360
26. van Lingen RG, van de Kerkhof PC, Seyger MM et al (2008) CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 158:1264-1272
27. Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC (2008) Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cellmacrophages. Arterioscler Thromb Vasc Biol 28:1647-1653
28. Casagrande V, Menghini R, Menini S et al (2012) Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 32:74-81
29. Shah Z, Pineda C, Kampfrath T et al (2011) Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 55:2-9
30. Brokopp CE, Schoenauer R, Richards P et al (2011) Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J 32:2713-2722
31. Chen SJ, Jiaang WT (2011) Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein. Curr Top Med Chem 11:1447-1463
32. Arakawa M, Mita T, Azuma K et al (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030-1070
33. Hildebrandt M, Schabath R (2008) SDF-1 (CXCL12) in haematopoiesis and leukaemia: impact of DPP IV/CD26. Front Biosci 13:1774-1779
34. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagonlike peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350
35. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581
36. Marx N, Kehrle B, Kohlhammer K et al (2002) PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703-710
37. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
38. Frederich R, Alexander JH, Fiedorek FT et al (2010) A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 122:16-27